[HTML][HTML] Xanthine oxidoreductase: A leading actor in cardiovascular disease drama

L Polito, M Bortolotti, MG Battelli, A Bolognesi - Redox Biology, 2021 - Elsevier
Cardiovascular diseases (CVD) are the leading cause of global mortality and their
pathogenesis lies mainly in the atherosclerotic process. There are close connections linking …

[HTML][HTML] Xanthine oxidoreductase: One enzyme for multiple physiological tasks

M Bortolotti, L Polito, MG Battelli, A Bolognesi - Redox biology, 2021 - Elsevier
Human xanthine oxidoreductase (XOR) is a multiple-level regulated enzyme, resulting from
a complicated evolutionary process that assigned it many physiological roles. The main …

[HTML][HTML] Xanthine oxidoreductase in atherosclerosis pathogenesis: Not only oxidative stress

MG Battelli, L Polito, A Bolognesi - Atherosclerosis, 2014 - Elsevier
Endothelial xanthine oxidoreductase (XOR) together with NAD (P) H oxidase and nitric
oxide (NO) synthase plays a physiologic role in inflammatory signalling, the regulation of NO …

Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications

CE Berry, JM Hare - The Journal of physiology, 2004 - Wiley Online Library
There is substantial evidence that oxidative stress participates in the pathophysiology of
cardiovascular disease. Biochemical, molecular and pharmacological studies further …

[HTML][HTML] Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?

L Polito, M Bortolotti, MG Battelli, A Bolognesi - Pharmacological Research, 2022 - Elsevier
The present review explores the role of xanthine oxidoreductase (XOR) in the development
and progression of chronic kidney disease (CKD). Human XOR is a multi-level regulated …

Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options

W Doehner, U Landmesser - Seminars in nephrology, 2011 - Elsevier
The association between increased uric acid (UA) levels and cardiovascular disease (CVD)
has been observed and studied for many decades. The value of UA as an independent …

[HTML][HTML] The role of xanthine oxidoreductase and uric acid in metabolic syndrome

MG Battelli, M Bortolotti, L Polito, A Bolognesi - Biochimica et Biophysica …, 2018 - Elsevier
Xanthine oxidoreductase (XOR) could contribute to the pathogenesis of metabolic syndrome
through the oxidative stress and the inflammatory response induced by XOR-derived …

[HTML][HTML] Hyperuricemia and endothelial function: From molecular background to clinical perspectives

T Maruhashi, I Hisatome, Y Kihara, Y Higashi - Atherosclerosis, 2018 - Elsevier
Uric acid is the end product of purine metabolism catalyzed by xanthine oxidase in humans.
In the process of purine metabolism, reactive oxygen species, including superoxide, are …

Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme

M Giulia Battelli, L Polito, M Bortolotti… - Current medicinal …, 2016 - ingentaconnect.com
The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine
catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity …

[HTML][HTML] The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors

N Liu, H Xu, Q Sun, X Yu, W Chen, H Wei… - … Medicine and Cellular …, 2021 - hindawi.com
Uric acid is the end product of purine metabolism in humans. Hyperuricemia is a metabolic
disease caused by the increased formation or reduced excretion of serum uric acid (SUA) …